Barriers Limit Sativex Access for Patients With Spasticity in UK

Barriers Limit Sativex Access for Patients With Spasticity in UK

303544

Barriers Limit Sativex Access for Patients With Spasticity in UK

Sativex (nabiximols), a cannabis-based oral spray approved in the U.K. to ease spasticity — or muscle stiffness and spasms — in adults with multiple sclerosis (MS), remains unavailable to many patients there, according to a report by the MS Society UK. Sativex is the only licensed form of medical cannabis for MS in the U.K., and has been deemed cost-effective by the National Institute for Health Case and Excellence (NICE). But fewer than half of…

You must be logged in to read/download the full post.